Trial Profile
a single-center, randomized, double-blind, placebo-controlled single, multi-dose, phase I study to evaluate the tolerability, pharmacokinetics of kangdaprevir sodium tables administrations in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Kangdaprevir sodium (Primary)
- Indications Chronic hepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sunshine Lake Pharma
- 17 Mar 2020 Status changed from recruiting to completed.
- 24 Jan 2018 New trial record